Nurix Therapeutics
✓ Verified ManufacturerAbout
Nurix Therapeutics, Inc. is a cutting-edge biopharmaceutical company based in San Francisco, California, specializing in targeted protein degradation technology to develop breakthrough medicines for cancer and autoimmune diseases. The company leverages its proprietary DEL-AI Discovery Engine, an advanced drug discovery platform that combines DNA-encoded libraries with artificial intelligence to identify and develop novel therapeutic candidates. Nurix focuses on translating the science of targeted protein degradation into clinical candidates with the potential to transform patient outcomes. The company operates with a dual approach, advancing both degrader molecules and drug-antibody conjugates through its robust clinical pipeline in oncology and immunology. As a publicly traded company on NASDAQ under the ticker NRIX, Nurix maintains strong investor relations and regularly presents at industry conferences. Their leadership team consists of E3 ligase pioneers and biotech veterans who drive innovation in this emerging therapeutic modality. The company has positioned itself at the forefront of precision medicine, utilizing protein degradation as a powerful mechanism to address previously undruggable targets. Through strategic partnerships and internal development programs, Nurix continues to expand its portfolio of potential therapies designed to outmatch complex diseases through sophisticated molecular approaches.